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Abstract Treatment with radiolabelled somatostatin ana-
logues is a promising new tool in the management of patients
with inoperable or metastasized neuroendocrine tumours.
Symptomatic improvement may occur with 177Lu-labelled
somatostatin analogues that have been used for peptide recep-
tor radionuclide therapy (PRRT). The results obtained with
177Lu-[DOTA0,Tyr3]octreotate (DOTATATE) are very en-
couraging in terms of tumour regression. Dosimetry studies
with 177Lu-DOTATATE as well as the limited side effects with
additional cycles of 177Lu-DOTATATE suggest that more
cycles of 177Lu-DOTATATE can be safely given. Also, if
kidney-protective agents are used, the side effects of this
therapy are few and mild and less than those from the use of
90Y-[DOTA0,Tyr3]octreotide (DOTATOC). Besides objective
tumour responses, the median progression-free survival is
more than 40 months. The patients' self-assessed quality of life
increases significantly after treatment with 177Lu-DOTATATE.
Lastly, compared to historical controls, there is a benefit in
overall survival of several years from the time of diagnosis in
patients treated with 177Lu-DOTATATE. These findings com-
pare favourably with the limited number of alternative thera-
peutic approaches. If more widespread use of PRRT can be
guaranteed, such therapy may well become the therapy of first
choice in patients with metastasized or inoperable neuroendo-
crine tumours.
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Introduction
In advanced and metastasized neuroendocrine tumours
(NET), the use of surgery, external beam radiotherapy and
chemotherapy as cytoreductive options is limited. The use
of somatostatin analogues such as lanreotide and octreotide
not only reduces hormonal overproduction resulting in
symptomatic relief, but has also been shown to increase
time to tumour progression in a placebo-controlled prospec-
tive study in patients with functional midgut neuroendocrine
tumours treated with long-acting octreotide [1]. Peptide
receptor scintigraphy in humans started with the demonstra-
tion of somatostatin receptor-positive tumours in patients us-
ing a radioiodinated somatostatin analogue [2]. Later, other
radiolabelled somatostatin analogues were developed, and
two of these subsequently became commercially available:
[111In-DTPA0]octreotide (Octreoscan) [3] and 99mTc-depreo-
tide (Neotect). Newer positron emission tomography radio-
pharmaceuticals have been developed.
In the early 1990s, treatment with radiolabelled somato-
statin analogues started in patients with NETs. Peptide re-
ceptor radionuclide therapy (PRRT) started initially with
[111In-DTPA0]octreotide with promising results such as
symptomatic disease control, but partial remissions were
rare [4, 5]. Lessons learned from these studies were that
severe toxicities such as bone marrow suppression, and even
myelodysplastic syndrome in patients treated with high dos-
ages of >100 GBq (>3 Gy bone marrow radiation dose), as
well as renal insufficiency and transient liver toxicity may
occur.
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The next generation of PRRT used a modified somato-
statin analogue, [Tyr3]octreotide, with a higher affinity for
the somatostatin receptor subtype-2. Thereby, a different
chelator, DOTA instead of DTPA, was used in order to
ensure a more stable binding of the intended β-emitting
radionuclide 90Y. Using this compound (90Y-[DOTA0,Tyr3]
octreotide (DOTATOC; OctreoTher, Novartis, Basel, Switzer-
land; Onalta, Molecular Insight Pharmaceuticals, Cambridge,
MA), different phase 1 and phase 2 PRRT trials have been
performed. Lastly 177Lu-based PRRT has been introduced
into clinical practice. This review discusses these compounds
and summarizes the results from their use.
Radionuclide characteristics
PRRT using 111In as the therapeutic radionuclide has rarely
been successful in terms of objective tumour response, due
to the small particle range of its auger electrons and therefore
low tissue penetration. 90Y is a more suitable radionuclide
with the emission of β-particles with a maximum energy of
2.27 MeV and tissue penetration of 12 mm. The half-life of
64 h is comparable with that of 111In. Dosimetric calculations
are however difficult due to its pure β-emission and doses has
to be estimated by the use of either 86Yor 111In as a surrogate
or the application of alternative methods such as 90Y PET or
bremsstrahlung imaging [6].
Following the first paper in 1968 [7] on the diagnostic
use of 177Lu for bone imaging there was little interest in its
β-emission characteristics for therapy until 1985 when Bard
et al. [8] described the use of 177Lu in the treatment of
arthritis in rabbits. 177Lu is a medium-energy β-emitter with
a maximum energy of 0.5 MeV and a maximal tissue pen-
etration of 2 mm. Its half-life is 6.7 days. 177Lu also emits
low-energy γ-rays at 208 and 113 keV with 10% and 6%
abundance, respectively, which allows scintigraphy and sub-
sequent dosimetry with the same therapeutic compound.
The shorter β-range of 177Lu provides better irradiation of
small tumours, in contrast to the longer β-range of 90Y which
allows more uniform irradiation in large tumours that may
show heterogeneous uptake. This was illustrated in an animal
model, in which a combination of 90Y- and 177Lu-labelled
somatostatin analogues demonstrated a better tumour re-
sponse than the use of each radiolabelled analogue separately
[9].
Chelator and peptide
For the coupling of the radionuclide and the somato-
statin analogue in PRRT, the chelator DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetra-acetic acid) is often
used. Several studies on 177Lu-based PRRT have investigated
the use of different somatostatin analogues, such as [DOTA0,
Tyr3]octreotide (DOTATOC) , [DOTA0,Tyr3]octreotate
(DOTATATE) and [DOTA0-1-Nal3]octreotide (DOTANOC)
[10–13]. The somatostatin analogue [DTPA0,Tyr3]octreotate
differs from [DTPA0,Tyr3]octreotide only in that the C-
terminal threoninol is replaced with threonine. However, sub-
tle changes in the structure of the chelator and the use of a
different radionuclide or peptide affects the binding affinities
for the different somatostatin receptor subtypes (Table 1) [14].
In a comparison in patients, it was found that the uptake of
radioactivity, expressed as a percentage of the injected dose
of 177Lu-DOTATATE, was comparable with the use of
177Lu-DOTATOC in the kidneys, spleen and liver, but was
three to four times higher in four out of five tumours [15].
Therefore, 177Lu-DOTATATE has a potential advantage be-
cause of the higher absorbed doses that can be achieved in
most tumours without increases in the doses to potentially
dose-limiting organs. Also, in tumours in the same patients
in a therapeutic setting, we found that the residence
times are in favour of 177Lu-DOTATATE in comparison with
177Lu-DOTATOC by a factor of 2.1 (Fig. 1) [16]. In contrast,
Forrer et al. [17] demonstrated no difference in tumour uptake
of 111In-DOTATATE and 111In-DOTATOC, whereas 111In-
DOTATOC showed a higher tumour-to-kidney absorbed dose
ratio. However, a low amount of peptide (10 μg) was admin-
istered to the patients without concomitant amino acid infu-
sion, whereas Esser et al. [16] used 200 μg peptide with amino
acid infusion, which corresponds exactly to the clinical
therapeutic setting. Wehrmann et al. [11] compared the bio-
distribution of 177Lu-DOTATATE and 177Lu-DOTANOC in
patients, and concluded that tumour uptake and absorbed
doses were comparable for the two radioligands, whereas
whole-body retention was lower for 177Lu-DOTATATE, and
therefore the authors advocated the therapeutic use of
177Lu-DOTATATE, because a lower whole-body retention
potentially implies a lower bone marrow toxicity.
Treatment protocols
Although most treatment protocols are much alike, mi-
nor differences do exist. All published studies on PRRT
using 177Lu-based somatostatin analogues used diagnostic
111In-DTPA-octreotide (Octreoscan), 68Ga-DOTANOC or
68Ga-DOTATOC with sufficient tumour uptake as a patient
inclusion criterion. Due to the need for kidney protection [18],
most groups combined treatment with some form of amino
acid infusion. The Rotterdam and Bad Berka groups use 2.5%
L-lysine and 2.5% L-arginine in 1,000 ml, while the Basel
group uses a 2,000-ml infusion of an amino acid solution
comprising Ringer’s lactated Hartmann solution, Proteinsteril
(B. Braun Medical), HEPA 8%, Mg 5-Sulfat (B. Braun
Medical) as mentioned by Forrer et al. [20, 21] to inhibit
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tubular reabsorption of the radiopeptide. The Hartmann-
HEPA solution typically contains 1% lysine, making the treat-
ment protocol in terms of renal protection less effective as
higher amounts of lysine lead to a greater reduction in renal
uptake of radioactivity [21]. This is striking, as Imhof et al.
[22] treated all patients from 1997 onwards with a coinfusion
of 1,000 ml physiological saline containing 20.7 mg/ml of
arginine and 20.0 mg/ml of lysine, which is more than in the
Ringer’s lactated Hartmann solution mentioned above. The
Milan group [23] used 25 g of lysine in 1,000 ml saline
infused over 4 h, followed by an additional 12.5 g of lysine
in 500 ml saline over 3 h twice daily on days 2 and 3 after
therapy. The recent report by the Gothenborg group [24] does
not mention the use of any form of kidney protection at all.
Wehrmann et al. [11] from the Bad Berka group studied
eight patients with metastasized NET who received therapy
initially with 177Lu-DOTANOC (mean injected activity
5,515 MBq, range 3,600–7,400 MBq), but continued the
therapy with 177Lu-DOTATATE in three patients (injected
activity not mentioned) as well as 61 patients who had one
to four cycles of solely 177Lu-DOTATATE (mean injected
activity 5,534 MBq, range 2,500–7,400 MBq). The ratio-
nale for the choice of which therapeutic scheme in each
patient was not clear. Forrer et al. used two cycles of
Table 1 Affinity profiles for
human somatostatin receptors
1–5 of a series of somatostatin
analogues. Values are half-
maximal inhibitory concentra-
tions (SEM) in nanomoles
Adapted from reference [14]
Peptide Somatostatin receptor
1 2 3 4 5
Somatostatin-28 5.2 (0.3) 2.7 (0.3) 7.7 (0.9) 5.6 (0.4) 4.0 (0.3)
Octreotide >10,000 2.0 (0.7) 187 (55) >1,000 22 (6)
DTPA-octreotide >10,000 12 (2) 376 (84) >1,000 299 (50)
In-DTPA-octreotide >10,000 22 (3.6) 182 (13) >1,000 237 (52)
DOTA-[Tyr3]octreotide >10,000 14 (2.6) 880 (324) >1,000 393 (84)
DOTA-[Tyr3]octreotate >10,000 1.5 (0.4) >1,000 453 (176) 547 (160)
DOTA-lanreotide >10,000 26 (3.4) 771 (229) >10,000 73 (12)
Y-DOTA-[Tyr3]octreotide >10,000 11 (1.7) 389 (135) >10,000 114 (29)
Y-DOTA-[Tyr3]octreotate >10,000 1.6 (0.4) >1,000 523 (239) 187 (50)
Y-DOTA-lanreotide >10,000 23 (5) 290 (105) >10,000 16 (3.4)
Fig. 1 Typical example of
better tumour uptake of
177Lu-DOTATATE (left) than
that of 177Lu-DOTATOC (right)
in the tumour of a patient with
a gastroenteropancreatic NET
which results in a longer mean
residence time (mean residence
time ratio 2.4 in favour of
DOTATATE in this example).
Adapted from reference [16]
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7,400 MBq 177Lu-DOTATOC with an 8-week interval in a
study in 3 out of 28 patients with advanced paraganglioma
and phaeochromocytoma and with predominantly small me-
tastases (<2 cm) [20] after a single cycle of 3,700 MBq/m2
90Y-DOTATOC. In the above-mentioned studies, it is im-
possible to ascertain the sole treatment effect of the 177Lu-
labelled peptide. In another study by the same authors [21]
and a further study by Frilling et al. [12] patients were
treated with a single cycle of 7,400 MBq 177Lu-DOTATOC
and those showing disease relapse after initial therapy with
7,400 MBq/m2 90Y-DOTATOC in two cycles. In a study by
Kwekkeboom et al., patients who had not previously re-
ceived PRRT were treated with 18.5 to 29.6 GBq of 177Lu-
DOTATATE usually in four cycles, to a maximum kidney
dose of 23 Gy and a bone marrow dose of 2 Gy [15]. In a
study by Bodei et al., patients were divided into two groups
and received 3.7–5.18 GBq per cycle or 5.18–7.4 GBq per
cycle with cumulative activities in the ranges 3.7–29.2 GBq
and 5.55–28.9 GBq, respectively [23].
Side effects
Consistent with two previous reports [25, 26], the side
effects of a maximum injected activity of 7,400 MBq per
cycle of 177Lu-DOTATATE were analysed in 504 patients
with gastroenteropancreatic (GEP) NETs [13]. Acute side
effects occurring within 24 h after the administration of the
radiopharmaceutical were nausea after 25% of administra-
tions, vomiting after 10%, and abdominal discomfort or pain
after 10%. Subacute haematological toxicity (WHO toxicity
grade 3 or 4) occurred 4–8 weeks after 3.6% of administra-
tions or, expressed on a per-patient basis, after at least one of
several treatments in 9.5% of patients. Factors associated
with a higher frequency of haematological toxicity grade 3
or 4 were age over 70 years at treatment start, previous
chemotherapy, creatinine clearance (estimated with Cock-
croft's formula) ≤60 ml/min, and the presence of bone
metastases. When these factors were tested together in mul-
tivariate logistic regression, low creatinine clearance was a
significant factor both for grade 3/4 thrombocytopenia
(p<0.001) and any haematological grade 3/4 toxicity (p<
0.001), whereas previous chemotherapy was less significant
in predicting thrombocytopenia (p<0.05). Creatinine clear-
ance≤60 ml/min was significantly more frequent in patients
aged 70 years or more (p<0.001, Chi-squared test). Tempo-
rary hair loss (WHO grade 1; no baldness) occurred in 62%
of patients. Serious delayed toxicities were observed in 9 of
the 504 patients. There were two patients with renal insuf-
ficiency, which was probably unrelated to treatment with
177Lu-DOTATATE in both. There were three patients with
serious liver toxicity, which was probably unrelated to
treatment in both. Lastly, there were four patients with
myelodysplastic syndrome, which was potentially treatment-
related in three. In six patients with a highly hormonally active
NET, a hormone-related crisis occurred after administration
due to massive release of bioactive substances [27]. Bodei et
al. [23] found no major acute or delayed renal or haemato-
logical toxicity (one grade 3 leukopenia and thrombocytope-
nia) in their cohort of 51 patients.
In three articles describing the use of 177Lu-DOTATOC
[12, 20, 21], no serious side effects, including kidney tox-
icity, were reported. However, in these studies a maximum
of 14.8 GBq 177Lu-DOTATOC was used in patients who
had relapsed after earlier treatment with 90Y- DOTATOC.
The reported nausea and vomiting in 26% of all treated
patients [15] were not reported separately in relation to
90Y- or 177Lu-DOTATATE treatment. Currently, there are
no reports of the side effects using 177Lu-DOTANOC.
Dosimetry
With the use of low-energy γ-rays at 208 and 113 keVemitted
by 177Lu, concomitantly with the therapeutic β-radiation, not
only can posttreatment scans be acquired, but patient dosim-
etry can also be performed. The absorbed radiation doses to
dose-limiting organs such as the kidneys and bone marrow are
calculated to better tailor the total cumulative activity that can
be administered to the individual patient. The absorbed radia-
tion dose to the kidneys varies widely between patients treated
with 177Lu-DOTATATE [15]. Based on calculations performed
in six patients with a limited tumour load, the radiation dose to
the bone marrow did not vary much between patients, and was
estimated at a mean of 0.07mGy/MBq (range 0.05–0.08 mGy/
MBq). Therefore, allowing a maximum of 2 Gy for the
absorbed dose to the bone marrow, the resulting cumulative
dose that can be given was fixed at 29.6 GBq [15]. In a study
by Werhmann et al. [11] in 69 patients the dose to the bone
marrow was also variable between patients, and the calculated
dose in most patients was 0.04±0.02 mGy/MBq (range 0.02–
0.08 mGy/MBq). This was confirmed in another study in 15
patients by Forrer et al., in which the calculated dose was
0.03 mGy/MBq [28]. In the study by Bodei et al. [23], in 12
of 51 patients the calculated bone marrow dose was 0.03mGy/
MBq with a cumulative dose in the range 0.5–1.3 Gy.
In addition, in 53% of 334 patients in whom unpublished
kidney dosimetry was performed, an upper limit of 23 Gy
for the absorbed dose to the kidneys would be reached with
a total cumulative administered dose of 33.3 GBq or more.
This means that with fixed dose regimens that show rela-
tively few side effects, a proportion of patients would be
under-treated. A study by Garkavij et al. [29] demonstrated
a large difference in calculated absorbed doses to the
kidneys depending on the dosimetry method used. The dose
varied from 1.15 mGy/MBq using the conventional planar
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abdominal background based method to 0.81 mGy/MBq
using SPECT calculations, which suggests under-treatment
if fixed maximal cumulative administered activities are
used. Similar kidney dosimetry calculations were reported
by Wehrmann et al. [11] and Bodei et al. [23]. Valkema et al.
[30] reported a relatively mild decrease in creatinine clear-
ance in patients treated with 177Lu-DOTATATE (median
3.8% per year) and a higher decrease in patients treated with
90Y-DOTATOC (median 7.3% per year), suggesting that
higher administered cumulative activities of 177Lu-DOTA-
TATEmay be feasible. More important is the observation from
this study that a creatinine clearance decrease of more than
25% per year is required for end-stage renal disease to develop
within 5 years. Such a decrease in kidney function was found
in only 1 of 37 patients treated with 177Lu-DOTATATE. Ad-
ditionally, hypertension and diabetes were found to be risk
factors for the development of kidney function loss after PRRT
[30, 31]. If these comorbidities are present, one would consider
lowering the upper limit for the absorbed dose to the kidneys,
as suggested by Bodei et al. [31]. Lastly, both the upper limits
for the maximum absorbed dose to the kidneys accepted in
PRRT and the calculation methods that are used for dosimetry
may be questioned. The accepted upper limit for the dose to the
kidneys of 23 Gy is derived from the experience of external
beam irradiation, which uses much higher dose rates than
PRRT. Also, the heterogeneous distribution of radioactivity
in the kidneys after PRRT invalidates the MIRDOSE-based
dosimetry models for low-energy emitting radionuclides such
as 177Lu [32]. This is in contrast to the findings of Swärd et al.
[24] of a significant decrease in glomerular filtration rate
(GFR, mean 80±4 ml/min per 1.73 m2 to 70±4 ml/min per
1.73 m2) at an unknown point in time during follow-up after
treatment with 177Lu-DOTATATE. This group, however, did
not mention the use of any form of renal protection at all.
Because of the huge variation between patients and the
limitations of the currently available methods for dosimetry
after PRRT, individual dosimetry for the absorbed doses to
both the bone marrow and the kidneys is desirable. Tailored or
individual dosimetry, currently based on urine collection, re-
peated imaging and blood sampling after therapy, is time-
consuming and labour-intensive. Therefore, individualized cal-
culations need to be simplified, and the need for a consensus as
to the preferred method for optimal dosimetry is obvious. The
maximum safe accumulated dose calculated using such an
individualizedmethodmay be higher in a considerable number
of patients and thereby this approach may also increase the
maximum cumulative radiation dose to the tumour.
Therapy response in PRRT-naive patients
Kwekkeboom et al. analysed responses to 177Lu-DOTA-
TATE treatment according to tumour type at 3 months after
the last therapy cycle in 310 patients [13]. Patients were
treated up to an intended cumulative activity of 22.2–
29.6 GBq (600–800 mCi). The overall objective tumour
response rate including complete remission (CR), PR and
minor response (MR) was 46% (Table 2) (Fig. 2). Prognostic
factors for predicting tumour remission (CR, PR orMR) as the
treatment outcomewere high uptake on diagnostic Octreoscan
imaging (p<0.01) and a Karnofsky performance score of >70
(p<0.05). A small percentage of patients who had either stable
disease (SD) or MR at their first two evaluations after therapy,
i.e. 6 and 12 weeks after the last treatment cycle, had a further
improvement in categorized tumour response at 6 months and
12 months, occurring in 4% of patients and 5% of patients,
respectively. Three of four patients with clinically nonfunc-
tioning neuroendocrine pancreatic tumours that were judged
inoperable before treatment with 177Lu-DOTATATE, and who
had a PR, were successfully operated on 6–12 months after
their last treatment, but the fourth died of postoperative com-
plications. In a small group of 21 patients treated with 177Lu-
DOTATATE by Garkavij et al. [29], 12 were evaluated for
objective response using RECIST criteria. PR was found in
two patients, MR in three and SD in five. In the last study
reported by Bodei et al. [23], 1 patient had CR, 14 had PR, 14
had MR, 14 had SD, and 9 had progressive disease (PD).
Another study evaluated the quality of life (QoL) in our
first 50 Dutch patients with metastatic somatostatin receptor-
positive GEP tumours treated with 177Lu-DOTATATE [33].
The patients completed the European Organization for the
Research and Treatment of Cancer Quality of Life Question-
naire C30 [34] before therapy and during the follow-up visit
6 weeks after the last cycle. A significant improvement in the
global health status/QoL scale was observed after therapy with
177Lu-DOTATATE. Furthermore, significant improvement
was observed in emotional and social function scales. The
symptom scores for fatigue, insomnia and pain decreased
significantly. Patients with proven tumour regression most
frequently had an improvement in QoL domains. However,
because of the lack of a control group in this study, some
placebo effect cannot be ruled out completely. This was also
confirmed in a later study in 265 patients by Khan et al. [35],
who demonstrated not only an improvement in QoL, but also
in Karnofsky performance score. Furthermore, no decrease in
QoL was found in patients without symptoms prior to PRRT.
There are no reports of the treatment outcome for
177Lu-DOTANOC or 177Lu-DOTATOC in patients who have
not received PRRT.
177Lu-DOTATATE versus other radiolabelled
somatostatin analogues
PRRT with 177Lu-DOTATATE is a promising new tool in
the management of patients with inoperable or metastasized
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neuroendocrine tumours, and it is of interest to compare the
results with those following the use of other radiolabelled
somatostatin analogues. The analogue that has been used
most often is 90Y-DOTATOC and the results with this analogue
are also very encouraging, although a direct, randomized com-
parison between 90Y-DOTATOC and 177Lu-DOTATATE is
lacking. The results of treatment with 90Y-DOTATOC in a
large group of patients with various NETs (treated in Basel,
Switzerland) have been reported [22]. If patients had a clinical
or biochemical response (numbers/percentages not stated) or
morphological disease control (morphological response or SD)
after the first treatment cycle, additional cycles were given. Of
1,109 patients, 378 (34.1%) showed amorphological response.
However, this was not base on RECISTor SWOG criteria. SD
was seen in 58 patients (5.2%). Median survival from diagno-
sis was 94.6 months. Data on median progression-free survival
were not given. Morphological, biochemical and clinical
responses, and high tumour uptake on somatostatin receptor
scintigraphy, were associated with longer median survival.
Since morphological, biochemical and/or clinical responses
were the criteria for treatment with additional cycles of
90Y-DOTATOC, a dose–effect relationship in terms of longer
survival cannot be ruled out. An extremely high percentage of
patients (9.2%) experienced severe permanent renal toxicity
(grade 4, GFR 15–29 ml/min per 1.73 m2; or grade 5,
GFR <15 ml/min per 1.73 m2 or dialysis) despite the use of
renal protection with 20.7 mg/ml of arginine (2% arginine)
and 20.0 mg/ml of lysine (2% lysine) in 1 l 0.9% NaCl.
However, it is not clear whether all study patients had received
this combination. In earlier studies from the same group
[36–38], the reports state that patients received the same
Hartmann-HEPA solution, as used in the Lu-DOTATOC-
treated patients from the same group.
Other reported percentages of tumour remission after
90Y-DOTATOC treatment vary (Table 2) [38–41]. There
may be several reasons why different results were found in
the centres performing trials with the same compound. First,
there may be differences in the administered doses and
dosing schemes. Some studies used dose-escalating
schemes, whereas others used fixed doses. Second, there
may be differences in patient and/or tumour selection. Several
patient and tumour characteristics are prognostic for treatment
outcome, such as amount of uptake on diagnostic Octreoscan
imaging, estimated total tumour burden and the extent of liver
involvement. Therefore, differences in patient selection may
play an important role in determining treatment outcome.
Table 2 Tumour responses in patients with NETs treated with different radiolabelled somatostatin analogues (adapted from reference [26])
Reference Ligand Number
of patients
Tumour response
CR PR MR SD PD
[31] 90Y-DOTATOC 21 0 6 (29%) NA 11 (52%) 4 (19%)
[37, 38] 90Y-DOTATOC 74 3 (4%) 15 (20%) NA 48 (65%) 8 (11%)
[39] 90Y-DOTATOC 33 2 (6%) 9 (27%) NA 19 (57%) 3 (9%)
[40] 90Y-DOTATOC 58 0 5 (9%) 7 (12%) 33 (61%) 10 (19%)
[13] 177Lu-DOTATATE 310 5 (2%) 86 (28%) 51 (16%) 107 (35%) 61 (20%)
[29] 177Lu-DOTATATE 12 0 2 (17%) 3 (25%) 5 (42%) 2 (17%)
[23] 177Lu-DOTATATE 51 1 (2%) 14 (27%) 13 (26%) 14 (27%) 9 (18%)
Fig. 2 Typical example of a
partial response (PR) in a
patient with a NET of the small
bowel with liver metastases
treated with 29.6 GBq
177Lu-DOTATATE. a CT
scan showing multiple liver
metastases before treatment.
b CT scan 6 weeks after
treatment with regression
of liver metastases, consistent
with a PR
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Third, there may be differences in tumour response criteria as
some centres use the WHO tumour response criteria and
others modified Southwest Oncology Group standard re-
sponse criteria, with or without sonography for tumour size
assessment. Finally, there may be centralized or decentralized
follow-up CT scoring.
Our analysis in patients treated with 177Lu-DOTATATE
indicated that the two most important prognostic factors for
a favourable treatment outcome were high patient perfor-
mance score and high uptake on pretreatment Octreoscan
imaging. It is obvious that different studies can only be reli-
ably compared if stratification for these factors is applied.
From the published data, such a stratified comparison cannot
be performed. Also, in order to establish which treatment
scheme and which radiolabelled somatostatin analogues or
combination of analogues is optimal, randomized trials are
needed.
Retreatment
Because PRRT rarely results in CR, tumour progression will
occur during follow-up. If the patient meets certain criteria
mainly concerning bone marrow reserve, kidney function
and tumour uptake on the diagnostic somatostatin receptor
scan, retreatment may be an option. Forrer et al. [21]
retreated 27 patients who had initially been treated with
90Y-DOTATOC (8 patients had 11,100 MBq/m2, 19 had
7,400 MBq/m2 in three and two cycles, respectively) with
a single cycle of 7.4 GBq 177Lu-DOTATOC. 177Lu-DOTATOC
was chosen to avoid possible renal toxicity due to the further
use of 90Y. Of these 27 patients, 14 had had a radiological
response (at least PR according to WHO criteria) after
the regular treatment with 90Y-DOTATOC. Benefit after
177Lu-DOTATOC was seen in 19 patients (70%): 12 had SD,
5 had MR, and 2 had PR. None of the patients with PR after
90Y-DOTATOC treatment had PD after a single cycle of
177Lu-DOTATOC. The authors concluded that retreatment with
177Lu-DOTATOC is feasible, safe and efficacious without
serious adverse events.
Recently, data on retreatment with two cycles of 7.4 GBq
of 177Lu-DOTATATE in 33 patients previously treated with
22.2– 29.6 GBq 177Lu-DOTATATE were reported [42]. Of
these 33 patients, 28 had had a radiological response (at
least MR) after the regular treatment with usually four cycles
of 177Lu-DOTATATE, and 5 had experienced a significant
clinical improvement. All had CT-assessed tumour progres-
sion before the start of retreatment. In 7 patients (24%)
renewed tumour size reduction was observed, and 7 (24%)
had SD at follow-up. No major side effects were observed
during a median follow-up of 16 months. It was concluded
that in the absence of treatment alternatives, this salvage
therapy is safe and can be effective in selected patients.
Options to improve PRRT
From animal experiments it can be inferred that 90Y-labelled
somatostatin analogues may be more effective in larger
tumours, whereas 177Lu-labelled somatostatin analogues
may be more effective in smaller tumours, but their combina-
tion may be even more effective [43]. Therefore, apart from
comparisons between radiolabelled octreotate and octreotide,
and between somatostatin analogues labelled with 90Y and
those labelled with 177Lu, PRRT with combinations of 90Y-
and 177Lu-labelled analogues should also be evaluated.
Future directions to improve this therapy may also in-
clude the use of radiosensitizing chemotherapeutic agents.
Chemosensitization with 5-fluorouracil (5-FU) in combina-
tion with 90Y-labelled antibody radioimmunotherapy is fea-
sible and safe [44]. Also, chemosensitization with 5-FU
combined with [111In-DTPA]octreotide treatment resulted
in symptomatic response in 71% of patients with NETs
[45], whereas other studies using only [111In-DTPA]octreo-
tide treatment have shown such responses in lower percen-
tages [4, 5]. Numerous trials on the effects of combined
chemotherapy and (fractionated) external beam radiotherapy
have been performed. In many of these, 5-FU was used.
More recent trials used the prodrug of 5-FU, capecitabine,
which has the advantage of oral administration. Also
with the combination of radiotherapy and capecitabine,
increased efficacy in terms of tumour growth control was
reported if compared to radiotherapy as a single treat-
ment modality [46]. If capecitabine is used at relatively
low doses (1,600–2,000 mg/m2 per day), grade 3 haema-
tological or other toxicity is rare [46, 47]. For these
reasons, after a pilot study to establish the safety of the
combined therapy protocol [48], we started a randomized
trial comparing treatment with 177Lu-octreotate with and
without capecitabine in patients with GEP NETs. Also,
attempts to improve the results of this type of therapy
may focus on further reducing the radiation absorbed
dose to normal tissues and organs, such as the kidneys
and bone marrow, or at increasing the receptor density on
the tumours, for instance via receptor upregulation. Both
strategies may increase the therapeutic window.
Intraarterial treatment in selected patients with a predominant
tumour load in the liver has been reported to be safe and
effective. McStay et al. [49] used [90Y-DOTA0,Tyr3]lanreotide
administered via the hepatic artery (mostly 2×1 GBq) to
treat 23 patients with NETs, and 3 of these patients
showed PR and 12 showed SD. However, 2 of the 3
patients with PR also had had concomitant embolization.
Clinical improvement and a decrease in serum tumour
markers were observed in 60% of the patients. Limouris
et al. [50] used [111In-DTPA0]octreotide (6.3 GBq per
injection and with a maximum of 12 injections per patient)
to treat 17 patients, and 9 of these patients showed CR or PR.
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Lastly, Kratochwil et al. [51] found a fourfold higher uptake
after intraarterial administration of [68Ga-DOTA0,Tyr3]
octreotide compared with intravenous administration in the
same patients. Therefore, in selected patients this type of
administration seems advantageous.
The use of PRRT as a neoadjuvant treatment has also been
advocated in animal studies by Breeman et al. [52] who
reported an increased survival in rats treated for 8 days with
177Lu-DOTATATE after infusion of 0.25×106 viable
CA20948 cells into the portal vein, which mimics liver micro-
metastases. In humans, the use of PRRT in previously judged
inoperable NETs has been described by Kaemmerer et al. [53]
in a case report with PRRT used in a neoadjuvant setting
before surgery, by Kwekkeboom et al. [13] who reported
that PRRT enabled surgery in four patients in a large
cohort of more than 500 patients, by Sowa-Staszczak et
al. [54] in two of six patients treated in a neoadjuvant
setting, and by Barber et al. [55] who found the same in five.
Conclusion
Treatment with radiolabelled somatostatin analogues is a prom-
ising new tool in the management of patients with inoperable or
metastasized neuroendocrine tumours. Treatment with 177Lu-
labelled somatostatin analogues that have been used in PRRT
may lead to symptomatic improvement. The results obtained
with 177Lu-DOTATATE are very encouraging in terms of tumour
regression. Dosimetry studies with 177Lu-DOTATATE as well as
the limited side effects after 177Lu-DOTATATE retreatment sug-
gest that there is room for more cycles of 177Lu-DOTATATE
than currently used. Also, if kidney protective agents are used,
the side effects of PRRT are few and mild, and less than from
90Y-DOTATOC. CR, PR orMRmay be achieved in almost 50%
of patients and the duration of the therapy response is more than
40months. The patients' self-assessed QoL increases significant-
ly after treatment with 177Lu-DOTATATE. Lastly, compared to
historical controls, patients treatedwith 177Lu-DOTATATE show
an increase in overall survival of several years from the time of
diagnosis. These data compare favourably with the limited
number of alternative treatment approaches. If more wide-
spread use of PRRTcan be guaranteed, such therapy may well
become the therapy of first choice in patients with metasta-
sized or inoperable NETs.
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